Emerging studies address critical Alzheimer’s disease (AD) mechanisms and therapies. Purdue University researchers demonstrated amyloid beta plaques induce lipid droplet accumulation in microglia, impairing their plaque-clearing ability, suggesting lipid metabolism as a therapeutic target. Separately, clinical trials initiated to evaluate semaglutide’s potential to slow cognitive decline in AD patients, reflecting increased interest in repurposing metabolic drugs for neurodegenerative conditions.